NO331351B1 - Forbindelser med veksthormonfrigjorende egenskaper - Google Patents
Forbindelser med veksthormonfrigjorende egenskaper Download PDFInfo
- Publication number
- NO331351B1 NO331351B1 NO20006699A NO20006699A NO331351B1 NO 331351 B1 NO331351 B1 NO 331351B1 NO 20006699 A NO20006699 A NO 20006699A NO 20006699 A NO20006699 A NO 20006699A NO 331351 B1 NO331351 B1 NO 331351B1
- Authority
- NO
- Norway
- Prior art keywords
- ethyl
- methylcarbamoyl
- naphthyl
- oxoethyl
- benzyl
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 98
- 108010051696 Growth Hormone Proteins 0.000 title claims abstract description 41
- 239000000122 growth hormone Substances 0.000 title claims abstract description 41
- 102000018997 Growth Hormone Human genes 0.000 title claims abstract 3
- 230000003578 releasing effect Effects 0.000 title description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 35
- 239000001257 hydrogen Substances 0.000 claims description 35
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 31
- -1 amino, phenyl Chemical group 0.000 claims description 29
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 26
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 17
- 125000001624 naphthyl group Chemical group 0.000 claims description 12
- 206010062767 Hypophysitis Diseases 0.000 claims description 11
- 210000003635 pituitary gland Anatomy 0.000 claims description 11
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 230000004936 stimulating effect Effects 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 5
- 239000003814 drug Substances 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 3
- YQIUOHNQOJDCBZ-WJJVUGRUSA-N (e)-4-(1-aminocyclobutyl)-n-[(2r)-1-[[(2r)-1-(4-hydroxypiperidin-1-yl)-1-oxo-3-phenylpropan-2-yl]-methylamino]-1-oxo-3-(4-phenylphenyl)propan-2-yl]-n-methylbut-2-enamide Chemical compound C([C@@H](N(C)C(=O)\C=C\CC1(N)CCC1)C(=O)N(C)[C@H](CC=1C=CC=CC=1)C(=O)N1CCC(O)CC1)C(C=C1)=CC=C1C1=CC=CC=C1 YQIUOHNQOJDCBZ-WJJVUGRUSA-N 0.000 claims description 3
- DZKZMXVJARCRLV-KPMWTHKRSA-N (e)-4-(1-aminocyclobutyl)-n-[(2r)-1-[[(2r)-1-(4-hydroxypiperidin-1-yl)-1-oxo-3-phenylpropan-2-yl]-methylamino]-1-oxo-3-(4-phenylphenyl)propan-2-yl]but-2-enamide Chemical compound C([C@@H](N(C)C(=O)[C@@H](CC=1C=CC(=CC=1)C=1C=CC=CC=1)NC(=O)\C=C\CC1(N)CCC1)C(=O)N1CCC(O)CC1)C1=CC=CC=C1 DZKZMXVJARCRLV-KPMWTHKRSA-N 0.000 claims description 3
- LDGXDMBXCGXVAJ-CTNZJEHSSA-N (e)-4-(1-aminocyclobutyl)-n-[(2r)-1-[[(2r)-1-[(3s)-3-[(dimethylamino)methyl]piperidin-1-yl]-1-oxo-3-phenylpropan-2-yl]-methylamino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n-methylbut-2-enamide Chemical compound C1[C@H](CN(C)C)CCCN1C(=O)[C@H](N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC1(N)CCC1)CC1=CC=CC=C1 LDGXDMBXCGXVAJ-CTNZJEHSSA-N 0.000 claims description 3
- VQPXWMYSKOQPPG-IVQLKPQISA-N (e)-5-amino-n-[(2r)-1-[[(2r)-1-(4-hydroxypiperidin-1-yl)-1-oxo-3-phenylpropan-2-yl]-methylamino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n,5-dimethylhex-2-enamide Chemical compound C([C@@H](N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC(C)(C)N)C(=O)N1CCC(O)CC1)C1=CC=CC=C1 VQPXWMYSKOQPPG-IVQLKPQISA-N 0.000 claims description 3
- QUEJGZUHNORKEW-MKVXCEBYSA-N (e)-5-amino-n-[(2r)-1-[[(2r)-1-(4-hydroxypiperidin-1-yl)-1-oxo-3-thiophen-2-ylpropan-2-yl]-methylamino]-1-oxo-3-(4-phenylphenyl)propan-2-yl]-n,3,5-trimethylhex-2-enamide Chemical compound C([C@@H](N(C)C(=O)\C=C(/C)CC(C)(C)N)C(=O)N(C)[C@H](CC=1SC=CC=1)C(=O)N1CCC(O)CC1)C(C=C1)=CC=C1C1=CC=CC=C1 QUEJGZUHNORKEW-MKVXCEBYSA-N 0.000 claims description 3
- PXXCTYHKGMNEKB-DUDRCQOBSA-N (e)-5-amino-n-[(2r)-1-[[(2r)-1-[(2s)-2-[(dimethylamino)methyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]-methylamino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n,5-dimethylhex-2-enamide Chemical compound CN(C)C[C@@H]1CCCN1C(=O)[C@H](N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC(C)(C)N)CC1=CC=CC=C1 PXXCTYHKGMNEKB-DUDRCQOBSA-N 0.000 claims description 3
- BRXWONQWOVVDSR-XSEBBUNHSA-N (e)-5-amino-n-[(2r)-1-[[(2r)-1-[(3s)-3-[(dimethylamino)methyl]piperidin-1-yl]-1-oxo-3-phenylpropan-2-yl]-methylamino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n,5-dimethylhex-2-enamide Chemical compound C1[C@H](CN(C)C)CCCN1C(=O)[C@H](N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC(C)(C)N)CC1=CC=CC=C1 BRXWONQWOVVDSR-XSEBBUNHSA-N 0.000 claims description 3
- MQALRGDLNLJOEJ-IYBWFBNASA-N (e)-5-amino-n-[(2r)-1-[[(2r)-1-[4-[(dimethylamino)methyl]piperidin-1-yl]-1-oxo-3-phenylpropan-2-yl]-methylamino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n,5-dimethylhex-2-enamide Chemical compound C1CC(CN(C)C)CCN1C(=O)[C@H](N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC(C)(C)N)CC1=CC=CC=C1 MQALRGDLNLJOEJ-IYBWFBNASA-N 0.000 claims description 3
- BNCSGGPCCBXTGD-VMPYOYAXSA-N (e)-5-amino-n-[(2r)-1-[[(2r)-3-(4-fluorophenyl)-1-(4-hydroxypiperidin-1-yl)-1-oxopropan-2-yl]-methylamino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n,3,5-trimethylhex-2-enamide Chemical compound C([C@@H](N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C(/C)CC(C)(C)N)C(=O)N1CCC(O)CC1)C1=CC=C(F)C=C1 BNCSGGPCCBXTGD-VMPYOYAXSA-N 0.000 claims description 3
- GASZOSARLZFODU-YONGIPRNSA-N (e)-5-amino-n-[(2r)-1-[[(2r)-3-(4-fluorophenyl)-1-(4-hydroxypiperidin-1-yl)-1-oxopropan-2-yl]-methylamino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n,5-dimethylhex-2-enamide Chemical compound C([C@@H](N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC(C)(C)N)C(=O)N1CCC(O)CC1)C1=CC=C(F)C=C1 GASZOSARLZFODU-YONGIPRNSA-N 0.000 claims description 3
- QMHMDNQBFPHEHG-KKLWWLSJSA-N 3-(aminomethyl)-n-methyl-n-[(2r)-1-[methyl-[(2r)-1-(4-methylpiperazin-1-yl)-1-oxo-3-phenylpropan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]benzamide Chemical compound C([C@@H](N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)C=1C=C(CN)C=CC=1)C(=O)N1CCN(C)CC1)C1=CC=CC=C1 QMHMDNQBFPHEHG-KKLWWLSJSA-N 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 150000002431 hydrogen Chemical class 0.000 claims description 3
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 claims description 3
- RDURIQJHVHWXMT-CCZICSFRSA-N (e)-5-amino-n,3,5-trimethyl-n-[(2r)-1-[methyl-[(2r)-1-(4-methylpiperazin-1-yl)-1-oxo-3-phenylpropan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]hex-2-enamide Chemical compound C([C@@H](N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C(/C)CC(C)(C)N)C(=O)N1CCN(C)CC1)C1=CC=CC=C1 RDURIQJHVHWXMT-CCZICSFRSA-N 0.000 claims description 2
- YELQOFRUOVMJKR-YWKCSOBASA-N (e)-5-amino-n,5-dimethyl-n-[(2r)-1-[methyl-[(2r)-1-(4-methylpiperazin-1-yl)-1-oxo-3-phenylpropan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]hex-2-enamide Chemical compound C([C@@H](N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC(C)(C)N)C(=O)N1CCN(C)CC1)C1=CC=CC=C1 YELQOFRUOVMJKR-YWKCSOBASA-N 0.000 claims description 2
- XXJWCXKFODRSHT-IYBWFBNASA-N (e)-n-[(2r)-1-[[(2r)-1-(4-hydroxypiperidin-1-yl)-1-oxo-3-phenylpropan-2-yl]-methylamino]-1-oxo-3-(4-phenylphenyl)propan-2-yl]-n,5-dimethyl-5-(methylamino)hex-2-enamide Chemical compound C([C@@H](N(C)C(=O)/C=C/CC(C)(C)NC)C(=O)N(C)[C@H](CC=1C=CC=CC=1)C(=O)N1CCC(O)CC1)C(C=C1)=CC=C1C1=CC=CC=C1 XXJWCXKFODRSHT-IYBWFBNASA-N 0.000 claims description 2
- 125000002883 imidazolyl group Chemical group 0.000 claims description 2
- 125000001041 indolyl group Chemical group 0.000 claims description 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
- 125000000842 isoxazolyl group Chemical group 0.000 claims description 2
- GMVVFIATRLQYGY-HKIDPNTFSA-N n-[(2r)-1-[[(2r)-1-[(2s)-2-[(dimethylamino)methyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]-methylamino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n-methyl-3-(methylaminomethyl)benzamide Chemical compound CNCC1=CC=CC(C(=O)N(C)[C@H](CC=2C=C3C=CC=CC3=CC=2)C(=O)N(C)[C@H](CC=2C=CC=CC=2)C(=O)N2[C@@H](CCC2)CN(C)C)=C1 GMVVFIATRLQYGY-HKIDPNTFSA-N 0.000 claims description 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims description 2
- 125000002971 oxazolyl group Chemical group 0.000 claims description 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 2
- 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
- 125000004076 pyridyl group Chemical group 0.000 claims description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 2
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 claims description 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims description 2
- 125000000335 thiazolyl group Chemical group 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 238000011282 treatment Methods 0.000 abstract description 42
- 239000000203 mixture Substances 0.000 abstract description 11
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 267
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 156
- 239000000243 solution Substances 0.000 description 90
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 87
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 78
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 71
- 239000002904 solvent Substances 0.000 description 62
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 60
- 239000011541 reaction mixture Substances 0.000 description 60
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 45
- 238000005160 1H NMR spectroscopy Methods 0.000 description 42
- 102100038803 Somatotropin Human genes 0.000 description 38
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 38
- 239000007864 aqueous solution Substances 0.000 description 37
- 239000000377 silicon dioxide Substances 0.000 description 36
- 238000004128 high performance liquid chromatography Methods 0.000 description 34
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 33
- 239000012043 crude product Substances 0.000 description 33
- 238000000034 method Methods 0.000 description 31
- 238000003818 flash chromatography Methods 0.000 description 30
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 30
- 235000019341 magnesium sulphate Nutrition 0.000 description 30
- 239000003480 eluent Substances 0.000 description 29
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 26
- 239000012044 organic layer Substances 0.000 description 24
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 22
- 239000008346 aqueous phase Substances 0.000 description 22
- 235000017557 sodium bicarbonate Nutrition 0.000 description 21
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 21
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 20
- 229920006395 saturated elastomer Polymers 0.000 description 20
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 19
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Substances CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 18
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 18
- FPIRBHDGWMWJEP-UHFFFAOYSA-N 1-hydroxy-7-azabenzotriazole Chemical compound C1=CN=C2N(O)N=NC2=C1 FPIRBHDGWMWJEP-UHFFFAOYSA-N 0.000 description 17
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 17
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 16
- 239000003153 chemical reaction reagent Substances 0.000 description 16
- AJGJINVEYVTDNH-GFCCVEGCSA-N (2r)-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]-3-phenylpropanoic acid Chemical compound CC(C)(C)OC(=O)N(C)[C@@H](C(O)=O)CC1=CC=CC=C1 AJGJINVEYVTDNH-GFCCVEGCSA-N 0.000 description 15
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 15
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 15
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 15
- 239000002253 acid Substances 0.000 description 15
- 238000004949 mass spectrometry Methods 0.000 description 15
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 14
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 14
- 238000010792 warming Methods 0.000 description 14
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 13
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 13
- 239000007858 starting material Substances 0.000 description 13
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 12
- 238000005481 NMR spectroscopy Methods 0.000 description 11
- NRPOEGFAIJAQIE-VOTSOKGWSA-N (e)-5-methyl-5-[(2-methylpropan-2-yl)oxycarbonylamino]hex-2-enoic acid Chemical compound CC(C)(C)OC(=O)NC(C)(C)C\C=C\C(O)=O NRPOEGFAIJAQIE-VOTSOKGWSA-N 0.000 description 10
- 229960000583 acetic acid Drugs 0.000 description 10
- 229910052799 carbon Inorganic materials 0.000 description 10
- 125000006239 protecting group Chemical group 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 10
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 9
- 239000000872 buffer Substances 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- WTGCDTYRZPRKIL-MRXNPFEDSA-N (2r)-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]-3-naphthalen-2-ylpropanoic acid Chemical compound C1=CC=CC2=CC(C[C@@H](N(C)C(=O)OC(C)(C)C)C(O)=O)=CC=C21 WTGCDTYRZPRKIL-MRXNPFEDSA-N 0.000 description 8
- 235000011054 acetic acid Nutrition 0.000 description 8
- 150000001412 amines Chemical class 0.000 description 8
- 230000008878 coupling Effects 0.000 description 8
- 238000010168 coupling process Methods 0.000 description 8
- 238000005859 coupling reaction Methods 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 235000019260 propionic acid Nutrition 0.000 description 8
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- BDNKZNFMNDZQMI-UHFFFAOYSA-N 1,3-diisopropylcarbodiimide Chemical compound CC(C)N=C=NC(C)C BDNKZNFMNDZQMI-UHFFFAOYSA-N 0.000 description 7
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 7
- 102100033367 Appetite-regulating hormone Human genes 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- BGRWYRAHAFMIBJ-UHFFFAOYSA-N diisopropylcarbodiimide Natural products CC(C)NC(=O)NC(C)C BGRWYRAHAFMIBJ-UHFFFAOYSA-N 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 239000012074 organic phase Substances 0.000 description 7
- 108090000765 processed proteins & peptides Proteins 0.000 description 7
- WBHQBSYUUJJSRZ-UHFFFAOYSA-M sodium bisulfate Chemical compound [Na+].OS([O-])(=O)=O WBHQBSYUUJJSRZ-UHFFFAOYSA-M 0.000 description 7
- 229910000342 sodium bisulfate Inorganic materials 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- DSCBERFCMRPLAS-VQHVLOKHSA-N (e)-3,5-dimethyl-5-[(2-methylpropan-2-yl)oxycarbonylamino]hex-2-enoic acid Chemical compound OC(=O)\C=C(/C)CC(C)(C)NC(=O)OC(C)(C)C DSCBERFCMRPLAS-VQHVLOKHSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 206010053759 Growth retardation Diseases 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 238000006731 degradation reaction Methods 0.000 description 5
- 229940088598 enzyme Drugs 0.000 description 5
- 238000004108 freeze drying Methods 0.000 description 5
- 231100000001 growth retardation Toxicity 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 238000002955 isolation Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- ZUSDIXVXKSYBLT-GOSISDBHSA-N (2r)-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]-3-(4-phenylphenyl)propanoic acid Chemical compound C1=CC(C[C@@H](N(C)C(=O)OC(C)(C)C)C(O)=O)=CC=C1C1=CC=CC=C1 ZUSDIXVXKSYBLT-GOSISDBHSA-N 0.000 description 4
- UPELCGTZMOPXQW-SNVBAGLBSA-N (2r)-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]-3-thiophen-2-ylpropanoic acid Chemical compound CC(C)(C)OC(=O)N(C)[C@@H](C(O)=O)CC1=CC=CS1 UPELCGTZMOPXQW-SNVBAGLBSA-N 0.000 description 4
- PNZXTZHRPMZLMQ-ZGIBFIJWSA-N (2r)-n-[(2r)-1-[(2s)-2-[(dimethylamino)methyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]-n-methyl-2-(methylamino)-3-naphthalen-2-ylpropanamide Chemical compound C([C@@H](N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC)C(=O)N1[C@@H](CCC1)CN(C)C)C1=CC=CC=C1 PNZXTZHRPMZLMQ-ZGIBFIJWSA-N 0.000 description 4
- WCDVYEGGLFDLDC-NPBSGPTKSA-N (2r)-n-[(2r)-1-[(3s)-3-[(dimethylamino)methyl]piperidin-1-yl]-1-oxo-3-phenylpropan-2-yl]-n-methyl-2-(methylamino)-3-naphthalen-2-ylpropanamide Chemical compound C([C@@H](N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC)C(=O)N1C[C@H](CN(C)C)CCC1)C1=CC=CC=C1 WCDVYEGGLFDLDC-NPBSGPTKSA-N 0.000 description 4
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- 101710111255 Appetite-regulating hormone Proteins 0.000 description 4
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 239000000095 Growth Hormone-Releasing Hormone Substances 0.000 description 4
- 102100022831 Somatoliberin Human genes 0.000 description 4
- 101710142969 Somatoliberin Proteins 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 150000001793 charged compounds Chemical class 0.000 description 4
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 239000003324 growth hormone secretagogue Substances 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- 230000001817 pituitary effect Effects 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 4
- IYEISOVBDWSDKB-JKSUJKDBSA-N (2r)-1-[(2s)-2-[(dimethylamino)methyl]pyrrolidin-1-yl]-2-(methylamino)-3-phenylpropan-1-one Chemical compound C([C@@H](NC)C(=O)N1[C@@H](CCC1)CN(C)C)C1=CC=CC=C1 IYEISOVBDWSDKB-JKSUJKDBSA-N 0.000 description 3
- OJJPOPSMBATGJE-DLBZAZTESA-N (2r)-1-[(3s)-3-[(dimethylamino)methyl]piperidin-1-yl]-2-(methylamino)-3-phenylpropan-1-one Chemical compound C([C@@H](NC)C(=O)N1C[C@H](CN(C)C)CCC1)C1=CC=CC=C1 OJJPOPSMBATGJE-DLBZAZTESA-N 0.000 description 3
- KXPZKQCKDCRKJQ-QGZVFWFLSA-N (2r)-1-[4-[(dimethylamino)methyl]piperidin-1-yl]-2-(methylamino)-3-phenylpropan-1-one Chemical compound C([C@@H](NC)C(=O)N1CCC(CN(C)C)CC1)C1=CC=CC=C1 KXPZKQCKDCRKJQ-QGZVFWFLSA-N 0.000 description 3
- XKYBAMFGOQDARS-LOYHVIPDSA-N (2r)-n-[(2r)-1-[4-[(dimethylamino)methyl]piperidin-1-yl]-1-oxo-3-phenylpropan-2-yl]-n-methyl-2-(methylamino)-3-naphthalen-2-ylpropanamide Chemical compound C([C@@H](N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC)C(=O)N1CCC(CN(C)C)CC1)C1=CC=CC=C1 XKYBAMFGOQDARS-LOYHVIPDSA-N 0.000 description 3
- SXVNAOBGFOYCBT-GQCTYLIASA-N (e)-4-[1-[(2-methylpropan-2-yl)oxycarbonylamino]cyclobutyl]but-2-enoic acid Chemical compound CC(C)(C)OC(=O)NC1(C\C=C\C(O)=O)CCC1 SXVNAOBGFOYCBT-GQCTYLIASA-N 0.000 description 3
- CTMVADOISWHDEP-UHFFFAOYSA-N 1-azaspiro[3.3]heptan-2-one Chemical compound N1C(=O)CC11CCC1 CTMVADOISWHDEP-UHFFFAOYSA-N 0.000 description 3
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 3
- 102100022749 Aminopeptidase N Human genes 0.000 description 3
- 108010049990 CD13 Antigens Proteins 0.000 description 3
- 102000051325 Glucagon Human genes 0.000 description 3
- 108060003199 Glucagon Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 102000004142 Trypsin Human genes 0.000 description 3
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 3
- 108010004977 Vasopressins Proteins 0.000 description 3
- 102000002852 Vasopressins Human genes 0.000 description 3
- 230000001133 acceleration Effects 0.000 description 3
- 125000002947 alkylene group Chemical group 0.000 description 3
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 3
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 3
- 229940098773 bovine serum albumin Drugs 0.000 description 3
- 238000004440 column chromatography Methods 0.000 description 3
- CZPLDJZYEHQPGJ-PKNBQFBNSA-N ethyl (e)-3,5-dimethyl-5-[(2-methylpropan-2-yl)oxycarbonylamino]hex-2-enoate Chemical compound CCOC(=O)\C=C(/C)CC(C)(C)NC(=O)OC(C)(C)C CZPLDJZYEHQPGJ-PKNBQFBNSA-N 0.000 description 3
- FEMLEJLXNKJPFL-CMDGGOBGSA-N ethyl (e)-5-methyl-5-[(2-methylpropan-2-yl)oxycarbonylamino]hex-2-enoate Chemical compound CCOC(=O)\C=C\CC(C)(C)NC(=O)OC(C)(C)C FEMLEJLXNKJPFL-CMDGGOBGSA-N 0.000 description 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 3
- 229960004666 glucagon Drugs 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 3
- 244000144972 livestock Species 0.000 description 3
- QOVQVKFKBHWTAA-MRVPVSSYSA-N n,n-dimethyl-1-[(3r)-piperidin-3-yl]methanamine Chemical compound CN(C)C[C@@H]1CCCNC1 QOVQVKFKBHWTAA-MRVPVSSYSA-N 0.000 description 3
- SWQDHDJAIYSTRF-UHFFFAOYSA-N n,n-dimethyl-1-piperidin-4-ylmethanamine Chemical compound CN(C)CC1CCNCC1 SWQDHDJAIYSTRF-UHFFFAOYSA-N 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000006722 reduction reaction Methods 0.000 description 3
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- CNVUYXYLHUYWKR-JTQLQIEISA-N tert-butyl (2s)-2-[(dimethylamino)methyl]pyrrolidine-1-carboxylate Chemical compound CN(C)C[C@@H]1CCCN1C(=O)OC(C)(C)C CNVUYXYLHUYWKR-JTQLQIEISA-N 0.000 description 3
- YDBPZCVWPFMBDH-QMMMGPOBSA-N tert-butyl (2s)-2-formylpyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C=O YDBPZCVWPFMBDH-QMMMGPOBSA-N 0.000 description 3
- CDFOYUMGBSSYSV-UHFFFAOYSA-N tert-butyl 2-oxo-1-azaspiro[3.3]heptane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C(=O)CC11CCC1 CDFOYUMGBSSYSV-UHFFFAOYSA-N 0.000 description 3
- SRFKYSQSLHKPOK-UHFFFAOYSA-N tert-butyl 4-[(dimethylamino)methyl]piperidine-1-carboxylate Chemical compound CN(C)CC1CCN(C(=O)OC(C)(C)C)CC1 SRFKYSQSLHKPOK-UHFFFAOYSA-N 0.000 description 3
- VNOWIHHJPAJYHL-UHFFFAOYSA-N tert-butyl n-(2-methyl-4-oxobutan-2-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC(C)(C)CC=O VNOWIHHJPAJYHL-UHFFFAOYSA-N 0.000 description 3
- QHSUFODBDZQCHO-UHFFFAOYSA-N tert-butyl n-(4-hydroxy-2-methylbutan-2-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC(C)(C)CCO QHSUFODBDZQCHO-UHFFFAOYSA-N 0.000 description 3
- RXXAPXBUARYXKY-RBUKOAKNSA-N tert-butyl n-[(2r)-1-[(2s)-2-[(dimethylamino)methyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]-n-methylcarbamate Chemical compound CN(C)C[C@@H]1CCCN1C(=O)[C@H](N(C)C(=O)OC(C)(C)C)CC1=CC=CC=C1 RXXAPXBUARYXKY-RBUKOAKNSA-N 0.000 description 3
- RFIBKTPXDQMOPZ-VQTJNVASSA-N tert-butyl n-[(2r)-1-[(3s)-3-[(dimethylamino)methyl]piperidin-1-yl]-1-oxo-3-phenylpropan-2-yl]-n-methylcarbamate Chemical compound C1[C@H](CN(C)C)CCCN1C(=O)[C@H](N(C)C(=O)OC(C)(C)C)CC1=CC=CC=C1 RFIBKTPXDQMOPZ-VQTJNVASSA-N 0.000 description 3
- ZYICIRQFYBWSJH-HXUWFJFHSA-N tert-butyl n-[(2r)-1-[4-[(dimethylamino)methyl]piperidin-1-yl]-1-oxo-3-phenylpropan-2-yl]-n-methylcarbamate Chemical compound C1CC(CN(C)C)CCN1C(=O)[C@H](N(C)C(=O)OC(C)(C)C)CC1=CC=CC=C1 ZYICIRQFYBWSJH-HXUWFJFHSA-N 0.000 description 3
- BLTGGAXYSDWZGG-DCMFLLSESA-N tert-butyl n-[(2r)-1-[[(2r)-1-[(2s)-2-[(dimethylamino)methyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]-methylamino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n-methylcarbamate Chemical compound CN(C)C[C@@H]1CCCN1C(=O)[C@H](N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)OC(C)(C)C)CC1=CC=CC=C1 BLTGGAXYSDWZGG-DCMFLLSESA-N 0.000 description 3
- IQTMLSAQFZXPQM-CZNDPXEESA-N tert-butyl n-[(2r)-1-[[(2r)-1-[4-[(dimethylamino)methyl]piperidin-1-yl]-1-oxo-3-phenylpropan-2-yl]-methylamino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n-methylcarbamate Chemical compound C1CC(CN(C)C)CCN1C(=O)[C@H](N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)OC(C)(C)C)CC1=CC=CC=C1 IQTMLSAQFZXPQM-CZNDPXEESA-N 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 229960003726 vasopressin Drugs 0.000 description 3
- GDUBFXWWALXNPA-GFCCVEGCSA-N (2r)-3-(4-fluorophenyl)-2-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]propanoic acid Chemical compound CC(C)(C)OC(=O)N(C)[C@@H](C(O)=O)CC1=CC=C(F)C=C1 GDUBFXWWALXNPA-GFCCVEGCSA-N 0.000 description 2
- ZQEBQGAAWMOMAI-ZETCQYMHSA-N (2s)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1C(O)=O ZQEBQGAAWMOMAI-ZETCQYMHSA-N 0.000 description 2
- HAAUASBAIUJHAN-LXOXETEGSA-N (4s)-4-[[(2s)-2-amino-4-methylsulfanylbutanoyl]amino]-5-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-(carboxymethylamino)-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1h-imidazol- Chemical compound C([C@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CCSC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(O)=O)C1=CN=CN1 HAAUASBAIUJHAN-LXOXETEGSA-N 0.000 description 2
- OVLICNUIZFPFKS-CNMKOAFZSA-N (e)-4-(1-aminocyclobutyl)-n-[(2r)-1-[[(2r)-1-(4-hydroxypiperidin-1-yl)-1-oxo-3-phenylpropan-2-yl]-methylamino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n-methylbut-2-enamide Chemical compound C([C@@H](N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC1(N)CCC1)C(=O)N1CCC(O)CC1)C1=CC=CC=C1 OVLICNUIZFPFKS-CNMKOAFZSA-N 0.000 description 2
- VSPLCPUFQOSRFS-ATQVSBGGSA-N (e)-4-(1-aminocyclobutyl)-n-[(2r)-1-[[(2r)-1-[4-(dimethylamino)piperidin-1-yl]-1-oxo-3-phenylpropan-2-yl]-methylamino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n-methylbut-2-enamide Chemical compound C1CC(N(C)C)CCN1C(=O)[C@H](N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC1(N)CCC1)CC1=CC=CC=C1 VSPLCPUFQOSRFS-ATQVSBGGSA-N 0.000 description 2
- FCMZCQIJRIUCEX-JTPWXFIDSA-N (e)-4-(1-aminocyclobutyl)-n-methyl-n-[(2r)-1-[methyl-[(2r)-1-(4-methylpiperazin-1-yl)-1-oxo-3-phenylpropan-2-yl]amino]-3-naphthalen-2-yl-1-oxopropan-2-yl]but-2-enamide Chemical compound C([C@@H](N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC1(N)CCC1)C(=O)N1CCN(C)CC1)C1=CC=CC=C1 FCMZCQIJRIUCEX-JTPWXFIDSA-N 0.000 description 2
- HTFURBDIZPLBAB-GQCTYLIASA-N (e)-4-[1-(butoxycarbonylamino)cyclobutyl]but-2-enoic acid Chemical compound CCCCOC(=O)NC1(C\C=C\C(O)=O)CCC1 HTFURBDIZPLBAB-GQCTYLIASA-N 0.000 description 2
- RAMWDJGOOVFUPC-VOTSOKGWSA-N (e)-5-(butoxycarbonylamino)-5-methylhex-2-enoic acid Chemical compound CCCCOC(=O)NC(C)(C)C\C=C\C(O)=O RAMWDJGOOVFUPC-VOTSOKGWSA-N 0.000 description 2
- WUBYIHZMLHDVHU-PCJYRNNZSA-N (e)-5-amino-n-[(2r)-1-[[(2r)-1-(4-hydroxypiperidin-1-yl)-1-oxo-3-phenylpropan-2-yl]-methylamino]-1-oxo-3-(4-phenylphenyl)propan-2-yl]-n,3,5-trimethylhex-2-enamide Chemical compound C([C@@H](N(C)C(=O)\C=C(/C)CC(C)(C)N)C(=O)N(C)[C@H](CC=1C=CC=CC=1)C(=O)N1CCC(O)CC1)C(C=C1)=CC=C1C1=CC=CC=C1 WUBYIHZMLHDVHU-PCJYRNNZSA-N 0.000 description 2
- QTHPIRFUBSGWQW-HQTNHTCJSA-N (e)-5-amino-n-[(2r)-1-[[(2r)-1-(4-hydroxypiperidin-1-yl)-1-oxo-3-phenylpropan-2-yl]-methylamino]-1-oxo-3-(4-phenylphenyl)propan-2-yl]-n,5-dimethylhex-2-enamide Chemical compound C([C@@H](N(C)C(=O)\C=C\CC(C)(C)N)C(=O)N(C)[C@H](CC=1C=CC=CC=1)C(=O)N1CCC(O)CC1)C(C=C1)=CC=C1C1=CC=CC=C1 QTHPIRFUBSGWQW-HQTNHTCJSA-N 0.000 description 2
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- IBCLKOLOJLBQDZ-VIFPVBQESA-N 1-o-tert-butyl 2-o-ethyl (2s)-pyrrolidine-1,2-dicarboxylate Chemical compound CCOC(=O)[C@@H]1CCCN1C(=O)OC(C)(C)C IBCLKOLOJLBQDZ-VIFPVBQESA-N 0.000 description 2
- YCXCRFGBFZTUSU-SNVBAGLBSA-N 1-o-tert-butyl 3-o-ethyl (3r)-piperidine-1,3-dicarboxylate Chemical compound CCOC(=O)[C@@H]1CCCN(C(=O)OC(C)(C)C)C1 YCXCRFGBFZTUSU-SNVBAGLBSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- IZHVBANLECCAGF-UHFFFAOYSA-N 2-hydroxy-3-(octadecanoyloxy)propyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)COC(=O)CCCCCCCCCCCCCCCCC IZHVBANLECCAGF-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 208000030507 AIDS Diseases 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 2
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- 102000015427 Angiotensins Human genes 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- OISQFPRPJCXSLW-IYBWFBNASA-N C(C1=CC=CC=C1)[C@H](C(=O)N1CCC(CC1)CN(C)C)N(C(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)N(C(=O)/C=C/CC(C)(C)NC(O)=O)C)C Chemical compound C(C1=CC=CC=C1)[C@H](C(=O)N1CCC(CC1)CN(C)C)N(C(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)N(C(=O)/C=C/CC(C)(C)NC(O)=O)C)C OISQFPRPJCXSLW-IYBWFBNASA-N 0.000 description 2
- 108090000087 Carboxypeptidase B Proteins 0.000 description 2
- 102000003670 Carboxypeptidase B Human genes 0.000 description 2
- 102000005572 Cathepsin A Human genes 0.000 description 2
- 108010059081 Cathepsin A Proteins 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 2
- 108090000317 Chymotrypsin Proteins 0.000 description 2
- 101800000414 Corticotropin Proteins 0.000 description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
- 208000014311 Cushing syndrome Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- 241001622557 Hesperia Species 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 208000008589 Obesity Diseases 0.000 description 2
- 102400000050 Oxytocin Human genes 0.000 description 2
- 101800000989 Oxytocin Proteins 0.000 description 2
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 description 2
- 108010067372 Pancreatic elastase Proteins 0.000 description 2
- 102000016387 Pancreatic elastase Human genes 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 2
- 102100024819 Prolactin Human genes 0.000 description 2
- 108010057464 Prolactin Proteins 0.000 description 2
- 108091008611 Protein Kinase B Proteins 0.000 description 2
- 102000005765 Proto-Oncogene Proteins c-akt Human genes 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- 208000020221 Short stature Diseases 0.000 description 2
- 102000005157 Somatostatin Human genes 0.000 description 2
- 108010056088 Somatostatin Proteins 0.000 description 2
- XDHAWHLFPAUKEO-HKIDPNTFSA-N [3-[[(2R)-1-[[(2R)-1-[(2S)-2-[(dimethylamino)methyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]-methylamino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-methylcarbamoyl]phenyl]methyl-methylcarbamic acid Chemical compound C(C1=CC=CC=C1)[C@H](C(=O)N1[C@@H](CCC1)CN(C)C)N(C(=O)[C@@H](CC1=CC2=CC=CC=C2C=C1)N(C(=O)C=1C=C(CN(C(O)=O)C)C=CC=1)C)C XDHAWHLFPAUKEO-HKIDPNTFSA-N 0.000 description 2
- 159000000021 acetate salts Chemical class 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000008186 active pharmaceutical agent Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 150000001299 aldehydes Chemical class 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 2
- 239000001099 ammonium carbonate Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000001925 catabolic effect Effects 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229960002376 chymotrypsin Drugs 0.000 description 2
- IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 description 2
- 229960000258 corticotropin Drugs 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000007857 degradation product Substances 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 238000004401 flow injection analysis Methods 0.000 description 2
- 108010077689 gamma-aminobutyryl-2-methyltryptophyl-2-methyltryptophyl-2-methyltryptophyl-lysinamide Proteins 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000002808 molecular sieve Substances 0.000 description 2
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 2
- 231100000957 no side effect Toxicity 0.000 description 2
- 235000020824 obesity Nutrition 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 description 2
- 229960001723 oxytocin Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- XNGIFLGASWRNHJ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O XNGIFLGASWRNHJ-UHFFFAOYSA-N 0.000 description 2
- 238000004987 plasma desorption mass spectroscopy Methods 0.000 description 2
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 2
- 229940097325 prolactin Drugs 0.000 description 2
- 230000017854 proteolysis Effects 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- LEHBURLTIWGHEM-UHFFFAOYSA-N pyridinium chlorochromate Chemical compound [O-][Cr](Cl)(=O)=O.C1=CC=[NH+]C=C1 LEHBURLTIWGHEM-UHFFFAOYSA-N 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 2
- 235000010265 sodium sulphite Nutrition 0.000 description 2
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 2
- 229960000553 somatostatin Drugs 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- CTVHINDANRPFIL-SECBINFHSA-N tert-butyl (3r)-3-formylpiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H](C=O)C1 CTVHINDANRPFIL-SECBINFHSA-N 0.000 description 2
- JGMMNOYMEULLTJ-NSHDSACASA-N tert-butyl (3s)-3-[(dimethylamino)methyl]piperidine-1-carboxylate Chemical compound CN(C)C[C@@H]1CCCN(C(=O)OC(C)(C)C)C1 JGMMNOYMEULLTJ-NSHDSACASA-N 0.000 description 2
- CLYRYADYCFAJML-PHCUSUGSSA-N tert-butyl n-[(2r)-1-[[(2r)-1-[(3s)-3-[(dimethylamino)methyl]piperidin-1-yl]-1-oxo-3-phenylpropan-2-yl]-methylamino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n-methylcarbamate Chemical compound C1[C@H](CN(C)C)CCCN1C(=O)[C@H](N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)OC(C)(C)C)CC1=CC=CC=C1 CLYRYADYCFAJML-PHCUSUGSSA-N 0.000 description 2
- 238000004809 thin layer chromatography Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- GGUBFICZYGKNTD-UHFFFAOYSA-N triethyl phosphonoacetate Chemical compound CCOC(=O)CP(=O)(OCC)OCC GGUBFICZYGKNTD-UHFFFAOYSA-N 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 210000002268 wool Anatomy 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- ZENPGVFRMNRSDE-UHFFFAOYSA-N (2-methyl-4-oxopentan-2-yl)carbamic acid Chemical compound CC(=O)CC(C)(C)NC(O)=O ZENPGVFRMNRSDE-UHFFFAOYSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- VIYKYVYAKVNDPS-HKGPVOKGSA-N (2s)-2-azanyl-3-[3,4-bis(oxidanyl)phenyl]propanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 VIYKYVYAKVNDPS-HKGPVOKGSA-N 0.000 description 1
- WZHKXNSOCOQYQX-FUAFALNISA-N (2s)-6-amino-2-[[(2r)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-[[(2s)-2-amino-3-(1h-imidazol-5-yl)propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(1h-indol-3-yl)propanoyl]amino]-3-phenylpropanoyl]amino]hexanamide Chemical compound C([C@H](N)C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CN=CN1 WZHKXNSOCOQYQX-FUAFALNISA-N 0.000 description 1
- WTGBIRGNNDATDA-ZCFIWIBFSA-N (3r)-3-formylpiperidine-1-carboxylic acid Chemical compound OC(=O)N1CCC[C@@H](C=O)C1 WTGBIRGNNDATDA-ZCFIWIBFSA-N 0.000 description 1
- HWYNYLXTVJYPOW-RXMQYKEDSA-N (3r)-piperidine-1,3-dicarboxylic acid Chemical compound OC(=O)[C@@H]1CCCN(C(O)=O)C1 HWYNYLXTVJYPOW-RXMQYKEDSA-N 0.000 description 1
- QBFYZYRGBIUFIV-QMMMGPOBSA-N (3s)-3-[(dimethylamino)methyl]piperidine-1-carboxylic acid Chemical compound CN(C)C[C@@H]1CCCN(C(O)=O)C1 QBFYZYRGBIUFIV-QMMMGPOBSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- AOGUDKCUEZSLHY-GQCTYLIASA-N (e)-5-amino-3,5-dimethylhex-2-enoic acid Chemical compound CC(N)(C)CC(/C)=C/C(O)=O AOGUDKCUEZSLHY-GQCTYLIASA-N 0.000 description 1
- VHDYBSATWGRVAK-RGXIPBOGSA-N (e)-5-amino-n-[(2r)-1-[[(2r)-1-(4-hydroxypiperidin-1-yl)-1-oxo-3-phenylpropan-2-yl]-methylamino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-n,3,5-trimethylhex-2-enamide Chemical compound C([C@@H](N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C(/C)CC(C)(C)N)C(=O)N1CCC(O)CC1)C1=CC=CC=C1 VHDYBSATWGRVAK-RGXIPBOGSA-N 0.000 description 1
- KPUIBITXUURMJF-BQYQJAHWSA-N (e)-5-methyl-5-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]hex-2-enoic acid Chemical compound CC(C)(C)OC(=O)N(C)C(C)(C)C\C=C\C(O)=O KPUIBITXUURMJF-BQYQJAHWSA-N 0.000 description 1
- 125000001989 1,3-phenylene group Chemical group [H]C1=C([H])C([*:1])=C([H])C([*:2])=C1[H] 0.000 description 1
- RXYPXQSKLGGKOL-UHFFFAOYSA-N 1,4-dimethylpiperazine Chemical compound CN1CCN(C)CC1 RXYPXQSKLGGKOL-UHFFFAOYSA-N 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- HHPGQKZOPPDLNH-OGFXRTJISA-N 2,3-dihydroxybutanedioic acid;ethyl (3r)-piperidine-3-carboxylate Chemical compound OC(=O)C(O)C(O)C(O)=O.CCOC(=O)[C@@H]1CCCNC1 HHPGQKZOPPDLNH-OGFXRTJISA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- NGHWWOXFYMDOPV-UHFFFAOYSA-N 2-[1-[(2-methylpropan-2-yl)oxycarbonylamino]cyclobutyl]acetic acid Chemical compound CC(C)(C)OC(=O)NC1(CC(O)=O)CCC1 NGHWWOXFYMDOPV-UHFFFAOYSA-N 0.000 description 1
- PABISXFQAHDPMS-UHFFFAOYSA-N 2-hydroxy-2-oxoacetate;(2-methyl-4-oxopentan-2-yl)azanium Chemical compound OC(=O)C(O)=O.CC(=O)CC(C)(C)N PABISXFQAHDPMS-UHFFFAOYSA-N 0.000 description 1
- SGRBRAQXECVTBV-UHFFFAOYSA-N 2-methyl-n-propan-2-ylbutan-2-amine Chemical compound CCC(C)(C)NC(C)C SGRBRAQXECVTBV-UHFFFAOYSA-N 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-M 3-Methylbutanoic acid Natural products CC(C)CC([O-])=O GWYFCOCPABKNJV-UHFFFAOYSA-M 0.000 description 1
- WKBGXDWFIPYTBR-UHFFFAOYSA-N 3-[methyl-[(2-methylpropan-2-yl)oxycarbonyl]amino]benzoic acid Chemical compound CC(C)(C)OC(=O)N(C)C1=CC=CC(C(O)=O)=C1 WKBGXDWFIPYTBR-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- LHJVMOIOTPJSLS-UHFFFAOYSA-N 3-methyl-3-[(2-methylpropan-2-yl)oxycarbonylamino]butanoic acid Chemical compound CC(C)(C)OC(=O)NC(C)(C)CC(O)=O LHJVMOIOTPJSLS-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 125000006847 BOC protecting group Chemical group 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 210000004366 CD4-positive T-lymphocyte Anatomy 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 101150041968 CDC13 gene Proteins 0.000 description 1
- BHUJQGBAMBWKHH-DUDRCQOBSA-N CN(C)C[C@@H]1CCCN1C(=O)[C@H](N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC(C)(C)NC(O)=O)CC1=CC=CC=C1 Chemical compound CN(C)C[C@@H]1CCCN1C(=O)[C@H](N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC(C)(C)NC(O)=O)CC1=CC=CC=C1 BHUJQGBAMBWKHH-DUDRCQOBSA-N 0.000 description 1
- 206010006895 Cachexia Diseases 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000031229 Cardiomyopathies Diseases 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010010149 Complicated fracture Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 206010013883 Dwarfism Diseases 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 208000001362 Fetal Growth Retardation Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010070531 Foetal growth restriction Diseases 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 208000036119 Frailty Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 101710119601 Growth hormone-releasing peptides Proteins 0.000 description 1
- 239000012981 Hank's balanced salt solution Substances 0.000 description 1
- 206010020100 Hip fracture Diseases 0.000 description 1
- 208000037171 Hypercorticoidism Diseases 0.000 description 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 1
- 206010021113 Hypothermia Diseases 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 208000023178 Musculoskeletal disease Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000000713 Nesidioblastosis Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 206010029748 Noonan syndrome Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 208000004286 Osteochondrodysplasias Diseases 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 201000010769 Prader-Willi syndrome Diseases 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 206010049416 Short-bowel syndrome Diseases 0.000 description 1
- 206010072610 Skeletal dysplasia Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 101710162629 Trypsin inhibitor Proteins 0.000 description 1
- 229940122618 Trypsin inhibitor Drugs 0.000 description 1
- 208000026928 Turner syndrome Diseases 0.000 description 1
- 208000009982 Ventricular Dysfunction Diseases 0.000 description 1
- JYBKTNVXRYRZCJ-XSEBBUNHSA-N [(E)-6-[[(2R)-1-[[(2R)-1-[(3S)-3-[(dimethylamino)methyl]piperidin-1-yl]-1-oxo-3-phenylpropan-2-yl]-methylamino]-3-naphthalen-2-yl-1-oxopropan-2-yl]-methylamino]-2-methyl-6-oxohex-4-en-2-yl]carbamic acid Chemical compound C1[C@H](CN(C)C)CCCN1C(=O)[C@H](N(C)C(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)N(C)C(=O)\C=C\CC(C)(C)NC(O)=O)CC1=CC=CC=C1 JYBKTNVXRYRZCJ-XSEBBUNHSA-N 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 229940124532 absorption promoter Drugs 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 201000005255 adrenal gland hyperfunction Diseases 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 1
- 235000011130 ammonium sulphate Nutrition 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 239000012062 aqueous buffer Substances 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- GWYFCOCPABKNJV-UHFFFAOYSA-N beta-methyl-butyric acid Natural products CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000010072 bone remodeling Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 1
- KXDHJXZQYSOELW-UHFFFAOYSA-N carbonic acid monoamide Natural products NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- LDHQCZJRKDOVOX-NSCUHMNNSA-N crotonic acid Chemical compound C\C=C\C(O)=O LDHQCZJRKDOVOX-NSCUHMNNSA-N 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000002933 cyclohexyloxy group Chemical group C1(CCCCC1)O* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004980 cyclopropylene group Chemical group 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000003795 desorption Methods 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000002283 elective surgery Methods 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 125000005678 ethenylene group Chemical group [H]C([*:1])=C([H])[*:2] 0.000 description 1
- RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 230000004129 fatty acid metabolism Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 208000030941 fetal growth restriction Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950006191 gluconic acid Drugs 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 229940074045 glyceryl distearate Drugs 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 108010015153 growth hormone releasing hexapeptide Proteins 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 1
- 201000008980 hyperinsulinism Diseases 0.000 description 1
- 230000002631 hypothermal effect Effects 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
- 125000005921 isopentoxy group Chemical group 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003253 isopropoxy group Chemical group [H]C([H])([H])C([H])(O*)C([H])([H])[H] 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000006193 liquid solution Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 230000005980 lung dysfunction Effects 0.000 description 1
- 230000004199 lung function Effects 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- QIRVGKYPAOQVNP-UHFFFAOYSA-N methylidenecyclobutane Chemical compound C=C1CCC1 QIRVGKYPAOQVNP-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003551 muscarinic effect Effects 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- DXASQZJWWGZNSF-UHFFFAOYSA-N n,n-dimethylmethanamine;sulfur trioxide Chemical group CN(C)C.O=S(=O)=O DXASQZJWWGZNSF-UHFFFAOYSA-N 0.000 description 1
- IDCJGSDAPFXTGB-UHFFFAOYSA-N n,n-dimethylpiperidin-4-amine;hydrochloride Chemical compound Cl.CN(C)C1CCNCC1 IDCJGSDAPFXTGB-UHFFFAOYSA-N 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 230000011164 ossification Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 235000011007 phosphoric acid Nutrition 0.000 description 1
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000017363 positive regulation of growth Effects 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000000541 pulsatile effect Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 1
- 229910052761 rare earth metal Inorganic materials 0.000 description 1
- 239000000018 receptor agonist Substances 0.000 description 1
- 229940044601 receptor agonist Drugs 0.000 description 1
- 238000006268 reductive amination reaction Methods 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 208000001076 sarcopenia Diseases 0.000 description 1
- 201000000980 schizophrenia Diseases 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 230000000580 secretagogue effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000002098 selective ion monitoring Methods 0.000 description 1
- 238000001877 single-ion monitoring Methods 0.000 description 1
- 208000019116 sleep disease Diseases 0.000 description 1
- 230000003860 sleep quality Effects 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 229910000104 sodium hydride Inorganic materials 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- LFKDJXLFVYVEFG-UHFFFAOYSA-N tert-butyl carbamate Chemical compound CC(C)(C)OC(N)=O LFKDJXLFVYVEFG-UHFFFAOYSA-N 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 230000005313 thymus development Effects 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- KJAMZCVTJDTESW-UHFFFAOYSA-N tiracizine Chemical compound C1CC2=CC=CC=C2N(C(=O)CN(C)C)C2=CC(NC(=O)OCC)=CC=C21 KJAMZCVTJDTESW-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 230000006492 vascular dysfunction Effects 0.000 description 1
- 230000006815 ventricular dysfunction Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0207—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-(X)4-C(=0), e.g. 'isosters', replacing two amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
- A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Hydrogenated Pyridines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA199800857 | 1998-06-30 | ||
| DKPA199801440 | 1998-11-09 | ||
| PCT/DK1999/000368 WO2000001726A1 (en) | 1998-06-30 | 1999-06-29 | Compounds with growth hormone releasing properties |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20006699D0 NO20006699D0 (no) | 2000-12-29 |
| NO20006699L NO20006699L (no) | 2001-02-28 |
| NO331351B1 true NO331351B1 (no) | 2011-12-05 |
Family
ID=26064788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20006699A NO331351B1 (no) | 1998-06-30 | 2000-12-29 | Forbindelser med veksthormonfrigjorende egenskaper |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP1100824B1 (cs) |
| JP (1) | JP4511040B2 (cs) |
| KR (1) | KR100907638B1 (cs) |
| CN (1) | CN1304424C (cs) |
| AT (1) | ATE500269T1 (cs) |
| AU (1) | AU771644B2 (cs) |
| BR (1) | BRPI9911756B1 (cs) |
| CA (1) | CA2334315C (cs) |
| CY (1) | CY1111509T1 (cs) |
| CZ (1) | CZ299648B6 (cs) |
| DE (1) | DE69943239D1 (cs) |
| DK (1) | DK1100824T3 (cs) |
| HU (1) | HUP0102460A3 (cs) |
| IL (1) | IL140044A0 (cs) |
| NO (1) | NO331351B1 (cs) |
| PL (1) | PL199853B1 (cs) |
| PT (1) | PT1100824E (cs) |
| RU (1) | RU2298547C2 (cs) |
| TW (1) | TW593337B (cs) |
| WO (1) | WO2000001726A1 (cs) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005504043A (ja) * | 2001-08-10 | 2005-02-10 | パラチン テクノロジーズ インク． | 生物学的に活性な金属ペプチド類のペプチド模倣体類 |
| US7476653B2 (en) | 2003-06-18 | 2009-01-13 | Tranzyme Pharma, Inc. | Macrocyclic modulators of the ghrelin receptor |
| KR20070010151A (ko) * | 2004-03-30 | 2007-01-22 | 사파이어 세라퓨틱스, 인크. | 성장 호르몬 분비촉진제를 이용하여 ｃ-반응성 단백질을감소시키는 방법 |
| US20070191283A1 (en) * | 2004-08-12 | 2007-08-16 | Rejuvenon Corporation | Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues |
| JP4954983B2 (ja) * | 2005-05-18 | 2012-06-20 | ファーマサイエンス・インコーポレイテッド | Ｂｉｒドメイン結合化合物 |
| RU2418807C2 (ru) | 2005-10-25 | 2011-05-20 | Аегера Терапьютикс Инк. | Соединения, связывающие bir домены iap |
| CU23558A1 (es) | 2006-02-28 | 2010-07-20 | Ct Ingenieria Genetica Biotech | Compuestos análogos a los secretagogos peptidicos de la hormona de crecimiento |
| BRPI0807046A2 (pt) | 2007-02-09 | 2015-05-26 | Tranzyme Pharma Inc | Composto, composição farmacêutica, métodos de tratar um distúrbio, uma doença cardiovascular e um paciente que sofre de motilidade gastrointestinal reduzida ou disfuncional e, kit. |
| CN107382827B (zh) * | 2017-04-14 | 2021-01-01 | 江苏普莱医药生物技术有限公司 | 氨基酸衍生物或其药学上可接受的盐及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3924506A1 (de) * | 1989-07-25 | 1991-01-31 | Hoechst Ag | Renin-hemmende aminooligohydroxy-derivate |
| NZ258412A (en) * | 1992-12-11 | 1997-01-29 | Merck & Co Inc | Spiro-fused piperidine derivatives and pharmaceutical compositions |
| BR9608909A (pt) * | 1995-06-22 | 1999-03-02 | Novo Nordisk As | Composto composição farmacêutica processos para estimular a liberação do hormônio do crescimento da patuitária e aumentar a velocidade e extensão do crescimento dos animais para aumentar a produção de leite ou lã de animais ou para para doenças e uso do composto |
| ATE424412T1 (de) * | 1995-12-22 | 2009-03-15 | Novo Nordisk As | Verbindungen mit wachstumshormon-freisetzenden eigenschaften |
| EP0923539B1 (en) * | 1996-07-22 | 2002-06-05 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| AU7906998A (en) * | 1997-06-20 | 1999-01-04 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
-
1999
- 1999-06-29 HU HU0102460A patent/HUP0102460A3/hu unknown
- 1999-06-29 AT AT99929114T patent/ATE500269T1/de active
- 1999-06-29 CA CA2334315A patent/CA2334315C/en not_active Expired - Lifetime
- 1999-06-29 JP JP2000558127A patent/JP4511040B2/ja not_active Expired - Lifetime
- 1999-06-29 DE DE69943239T patent/DE69943239D1/de not_active Expired - Lifetime
- 1999-06-29 PT PT99929114T patent/PT1100824E/pt unknown
- 1999-06-29 EP EP99929114A patent/EP1100824B1/en not_active Expired - Lifetime
- 1999-06-29 IL IL14004499A patent/IL140044A0/xx not_active IP Right Cessation
- 1999-06-29 CN CNB998080861A patent/CN1304424C/zh not_active Expired - Fee Related
- 1999-06-29 KR KR1020007015040A patent/KR100907638B1/ko not_active Expired - Lifetime
- 1999-06-29 AU AU46038/99A patent/AU771644B2/en not_active Ceased
- 1999-06-29 BR BRPI9911756A patent/BRPI9911756B1/pt not_active IP Right Cessation
- 1999-06-29 PL PL345204A patent/PL199853B1/pl unknown
- 1999-06-29 DK DK99929114.9T patent/DK1100824T3/da active
- 1999-06-29 RU RU2001102617/04A patent/RU2298547C2/ru active
- 1999-06-29 WO PCT/DK1999/000368 patent/WO2000001726A1/en not_active Ceased
- 1999-06-29 CZ CZ20004565A patent/CZ299648B6/cs not_active IP Right Cessation
- 1999-08-18 TW TW088114089A patent/TW593337B/zh not_active IP Right Cessation
-
2000
- 2000-12-29 NO NO20006699A patent/NO331351B1/no not_active IP Right Cessation
-
2011
- 2011-06-01 CY CY20111100528T patent/CY1111509T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT1100824E (pt) | 2011-06-16 |
| PL199853B1 (pl) | 2008-11-28 |
| NO20006699L (no) | 2001-02-28 |
| PL345204A1 (en) | 2001-12-03 |
| IL140044A0 (en) | 2002-02-10 |
| KR20010053310A (ko) | 2001-06-25 |
| DE69943239D1 (de) | 2011-04-14 |
| RU2298547C2 (ru) | 2007-05-10 |
| HUP0102460A3 (en) | 2001-12-28 |
| BR9911756A (pt) | 2001-04-03 |
| JP4511040B2 (ja) | 2010-07-28 |
| DK1100824T3 (da) | 2011-06-20 |
| BRPI9911756B1 (pt) | 2016-06-14 |
| AU771644B2 (en) | 2004-04-01 |
| CN1307588A (zh) | 2001-08-08 |
| TW593337B (en) | 2004-06-21 |
| AU4603899A (en) | 2000-01-24 |
| CN1304424C (zh) | 2007-03-14 |
| JP2002519436A (ja) | 2002-07-02 |
| WO2000001726A1 (en) | 2000-01-13 |
| CZ299648B6 (cs) | 2008-10-01 |
| EP1100824B1 (en) | 2011-03-02 |
| CZ20004565A3 (en) | 2001-06-13 |
| HUP0102460A2 (hu) | 2001-11-28 |
| ATE500269T1 (de) | 2011-03-15 |
| CY1111509T1 (el) | 2015-08-05 |
| EP1100824A1 (en) | 2001-05-23 |
| CA2334315A1 (en) | 2000-01-13 |
| CA2334315C (en) | 2011-07-26 |
| NO20006699D0 (no) | 2000-12-29 |
| KR100907638B1 (ko) | 2009-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2243215C2 (ru) | Производные пиперидинкарбоновых кислот, фармацевтические композиции, содержащие их, способ стимуляции секреции гормона роста | |
| US6576648B2 (en) | Compound with growth hormone releasing properties | |
| US6303620B1 (en) | Compounds with growth hormone releasing properties | |
| US6127341A (en) | Compounds with growth hormone releasing properties | |
| NO312242B1 (no) | Forbindelser med veksthormonfrigjörende egenskaper, farmasöytiske preparater som omfatter dissse, samt anvendelse avforbindelsene til fremstilling av medikamenter | |
| EP1005484A1 (en) | Compounds with growth hormone releasing properties | |
| NO331351B1 (no) | Forbindelser med veksthormonfrigjorende egenskaper | |
| WO1996024580A1 (en) | Compounds with growth hormone releasing properties | |
| US5919777A (en) | Compounds with growth hormone releasing properties | |
| WO1996024587A1 (en) | Compounds with growth hormone releasing properties | |
| US7576062B2 (en) | Compounds with growth hormone releasing properties | |
| US6566337B1 (en) | Compounds with growth hormone releasing properties | |
| ES2361606T3 (es) | Composiciones con propiedades de liberación de hormonas del crecimiento. | |
| MXPA00012489A (en) | Compounds with growth hormone releasing properties | |
| EP1127071A1 (en) | Compounds with growth hormone releasing properties | |
| MXPA00010585A (en) | Compounds with growth hormone releasing properties | |
| IL149049A (en) | 2 - amino - n - [(1r) - 2 - [(3r) - 3 benzyl - 3 - (benzyl - 3 - (n', n', n - trimethylhydrazinocarbonyl) piperidin - 1 - yl] - 1 - (1h - indol - 3 - ylmethyl) - 2 oxoethyl] - 2 - methylpropionamide, pharmaceutical composition comprising it and its use for the manufacturing of medicaments for releasing growth hormone |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: HELSINN HEALTHCARE SA, CH |
|
| MM1K | Lapsed by not paying the annual fees |